

BILL SUMMARY
1st Session of the 52nd Legislature

Bill No.:	SB 934
Version:	FULLPCS1
Author:	Sen. Anderson/Rep. Schwartz
Date:	March 30, 2009
Impact:	\$0

Bill Summary

Research Analyst: Marcia Goff

The PCS1 for Engrossed SB 934 provides that typical and atypical antipsychotics will also be exempt from any product-based prior authorization program, in addition to any preferred drug list, in the drug utilization review of the Oklahoma Health Care Authority.

Fiscal Summary

Fiscal Analyst: Mark Newman

The FULLPCS1 for SB 934 exempts antipsychotic medications from any Medicaid preferred drug list or any product-based prior authorization program, unless clinically recommended by the Drug Utilization Review Board and approved by the Chief Medical Officer of the Oklahoma Health Care Authority (OHCA) or when there is a generic equivalent drug available.

Fiscal Analysis

Based on estimates provided by OHCA, the FULLPCS1 for SB 934 will have no fiscal impact on appropriations or appropriated agencies. This legislation exempts drugs in this category for clinical purposes or when a generic equivalent is available. The recent development and marketing of specific generic antipsychotic medications will allow OHCA to realize additional savings based on drug rebates and discounts related to the use of preferred drugs.

Long Term Fiscal Considerations

None

Fiscal Analysis Reviewed By:

Janice Buchanan

House Fiscal Director